JPRN-jRCT2031200346进行中（未招募）1 期
ONO-4578-05:Phase 1 study of ONO-4578 given as combinations of ONO-4578, ONO-4538, docetaxel and ramucirumab in subjects with metastatic non-small cell lung cancer who have had disease progression during or after one prior first-line anti-PD-(L) 1 antibody and platinum-based chemotherapy for advanced/metastatic disease
Osawa Masahiro0 个研究点目标入组 40 人开始时间: 2021年2月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Clinical stage III B/ III C with unsuitable for radical irradiation, Clinical stage IV or recurrent non-small cell lung cancer
- •2. Life expectancy of at least 3 months
- •3. Patients with ECOG performance status 0 or 1
排除标准
- •1. Patients with severe complication
- •2. Patients with multiple primary cancers
研究者
相似试验
进行中（未招募）
1 期
ONO-4578-04:ONO-4578 Phase 1 Studymetastatic pancreatic cancerJPRN-jRCT2031200286Hirashima Yoshinori60
进行中（未招募）
1 期
ONO-4578-03:ONO-4578 Phase 1 StudyJPRN-jRCT2051200096Hirashima Yoshinori30
招募中
1 期
ONO-4578-02:ONO-4578 Phase 1 Studynresectable colorectal cancerJPRN-jRCT2031200215Hirashima Yoshinori36
进行中（未招募）
1 期
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiationJPRN-jRCT2051210045Osawa Masahiro75
进行中（未招募）
1 期
Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerColorectal CancerNCT06547385Ono Pharmaceutical Co. Ltd40